ImmunoCellular Therapeutics (IMUC) Announces Presentation of Updated ICT-107 Phase 2 Data in GBM
Tweet Send to a Friend
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) announced the presentation of updated immune monitoring data from the phase 2 trial of ICT-107 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
